Amir London, CEO of Kamada Pharmaceuticals, was recently a guest on Benzinga's All-Access.
Kamada is a global biopharmaceutical company with a portfolio of assets indicated for rare and serious conditions. The company reports it is a leader in the specialty plasma-derived field, focused on diseases with limited treatment alternatives.
Mr. London was on the program to discuss exciting developments in the company's development pipeline as well as Mr. London's strategy for M&A.
